Built on a history of developing distinctive chromogens to differentiate
morphology on a single slide, Diagnostic BioSystems introduces a
portfolio of five Mosaic Multiplex™ Lung Cancer Kits for use in tissue
analysis of suspected Lung Cancer patients. Pathologists are challenged
with scarce tissue availability in patients with cancer. DBS is
addressing the tissue challenge with the Mosaic Multiplex ™ kits
enabling testing of multiple analytes on one slide with a complete kit
optimized for the DBS Mosaic 360™ System automated platform for lab to
lab standardized results.
The Mosaic System™ also includes a new line of “plug and play” reagents
optimized on the Mosaic 360™ platform to provide convenience for the
Histology Technologist in the Pathology laboratory.
“Diagnostic Biosystems is focused on developing clinically relevant
tools for pathologists. We believe it is important to provide the most
information with the limited tissue available in cancer patients today.
Our standardized Mosaic Multiplex™ lung cancer kits” are focused on
solving this problem,” said Dr. Bipin Gupta, PhD, President & CEO of
Diagnostic BioSystems.
During the USCAP, Diagnostic BioSystems will sponsor a Pathologist
Roundtable event on Tuesday, March 20, 2012 in Vancouver BC to discuss
advances in the use of Multiplex Kits in the analysis of suspected
cancers. Two industry experts, Dr. Omar Hameed from Vanderbilt and Dr.
Arundhati Rao from Scott & White Healthcare System, will join Marc Key
Ph.D., DBS Scientific Advisor, in leading these discussions.
http://www.businesswire.com/news/calgaryherald/20120319005615/en/Diagnostic-BioSystems-Launches-Automated-IHC-Multiplex-Platform
No comments:
Post a Comment